Insider Selling: Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Sells $12,581.14 in Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) COO Jian Xie sold 689 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $18.26, for a total value of $12,581.14. Following the sale, the chief operating officer now owns 336,136 shares in the company, valued at approximately $6,137,843.36. This represents a 0.20 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Fulgent Genetics Price Performance

FLGT stock opened at $18.30 on Friday. Fulgent Genetics, Inc. has a one year low of $16.56 and a one year high of $30.68. The stock has a market cap of $559.80 million, a price-to-earnings ratio of -3.32 and a beta of 1.51. The company has a fifty day moving average price of $19.79 and a two-hundred day moving average price of $21.11.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on FLGT. Piper Sandler dropped their target price on shares of Fulgent Genetics from $26.00 to $22.00 and set a “neutral” rating on the stock in a report on Monday, November 11th. StockNews.com lowered Fulgent Genetics from a “hold” rating to a “sell” rating in a research note on Wednesday.

Institutional Trading of Fulgent Genetics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Asset Dedication LLC bought a new position in Fulgent Genetics in the 2nd quarter valued at about $33,000. nVerses Capital LLC acquired a new position in shares of Fulgent Genetics in the second quarter valued at approximately $43,000. Signaturefd LLC increased its stake in shares of Fulgent Genetics by 103.6% during the second quarter. Signaturefd LLC now owns 2,225 shares of the company’s stock worth $44,000 after purchasing an additional 1,132 shares during the period. Point72 DIFC Ltd acquired a new stake in Fulgent Genetics during the 3rd quarter worth approximately $46,000. Finally, Canada Pension Plan Investment Board bought a new stake in Fulgent Genetics in the 2nd quarter valued at $63,000. Institutional investors own 48.06% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases.